(Q36175710)

12 August 2017

1 reference

title

The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview (English)

1 reference

12 August 2017

1 reference

Thomas N Ferraro

1

1 reference

12 August 2017

Russell J Buono

series ordinal

2

1 reference

12 August 2017

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

18-36

1 reference

Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Choroid plexus transporters for drugs and other xenobiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The genetic polymorphism of drug transporters: functional analysis approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Potential role of drug transporters in the pathogenesis of medically intractable epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The drug resistance-related protein LRP is the human major vault protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Pharmacokinetics of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Metabolism and excretion of mood stabilizers and new anticonvulsants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Clinical pharmacokinetics of levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Specific ligand binding on genetic variants of human alpha1-acid glycoprotein studied by circular dichroism spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha1-acid glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Structural analysis and fatty acid-binding properties of two Croatian variants of human serum albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Interpatient and intrapatient variability in phenytoin protein binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Effect of glycosylation on carbamazepine-serum protein binding in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Molecular mechanisms of genetic polymorphisms of drug metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Genetic Aspects of Drug Disposition and Therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Mephenytoin hydroxylation deficiency: kinetics after repeated doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Genetically determined variability in acetylation and oxidation. Therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Cytochrome P450 isozymes and antiepileptic drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Functional protein-protein interaction of drug metabolizing enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

Metabolism of valproic acid by hepatic microsomal cytochrome P-450

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Clinical pharmacology and pharmacokinetics of oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Tiagabine pharmacology in profile

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The neurobiology of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Channelopathies as a genetic cause of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Electrophysiological and pharmacological properties of the human brain type IIA Na+ channel expressed in a stable mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Molecular determinants of Na+ channel function in the extracellular domain of the beta1 subunit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Genes and mutations in human idiopathic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Genetic association studies in epilepsy: "the truth is out there".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Ca2+ channel beta-subunits: structural insights AID our understanding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Modulation of gating currents of the Ca(v)3.1 calcium channel by alpha 2 delta 2 and gamma 5 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Zonisamide enhances slow sodium inactivation in Myxicola

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Mechanisms of T-type calcium channel blockade by zonisamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Antagonism of convulsions but failure to enhance GABA(A) receptor function by felbamate in mice tolerant to diazepam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Gabapentin and vigabatrin increase GABA in the human neocortical slice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Selective blockade of N-type calcium channels by levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Alternative splicing in the voltage-sensing region of N-Type CaV2.2 channels modulates channel kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Increased expression of P/Q-type Ca2+ channel alpha1A subunit mRNA in cerebellum of N-type Ca2+ channel alpha1B subunit gene-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Calcium current block by (-)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl- current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Electrophysiology of benzodiazepine receptor ligands: multiple mechanisms and sites of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Affinity of various benzodiazepine site ligands in mice with a point mutation in the GABA(A) receptor gamma2 subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Human brain GABA transaminase tissue distribution and molecular expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Molecular basis of inherited epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Systematic investigation of genetic variability in 111 human genes-implications for studying variable drug response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

SNP discovery and typing technologies for pharmacogenomics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

Valproate and sodium currents in cultured hippocampal neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

Calcium channel alpha(2)delta subunits-structure and Gabapentin binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.04.010

7 January 2021

10.1016/J.YEBEH.2005.04.010

Identifiers

DOI

1 reference

12 August 2017

1 reference